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Heart failure (HF), a major public health burden affecting 2% of industrialized populations, 
is a syndrome resulting from structural or functional myocardial impairment leading to 
inadequate cardiac output to meet the body’s metabolic demands (1). Half of HF patients 
present systolic dysfunction (systolic-HF), also called reduced ejection fraction (HF-REF), a 
disease related to various causes including idiopathic Dilated Cardiomyopathy (DCM) and 
Coronary Artery Diseases (CAD) (ischemic-HF). HF is usually a multifactorial disease but 
the genetic variants contributing to its susceptibility or its severity may be different 
according to its underlying causes (2) and their identification is only beginning. 
 
A previous genome wide association study (GWAS) (3) identified two single nucleotide 
polymorphisms (SNPs) associated with DCM: rs2234962 within BAG3 gene (B-cell 
lymphoma 2-associated athanogene 3) and rs10927875 within a locus encompassing five 
genes including HSPB7 (heat shock 27 kDa protein family, member 7) (further called 
HSPB7 locus). Other studies also reported associations between polymorphisms in the 
HSPB7 locus and HF (4-6), two of them assessing the implication of the locus in the 
subgroup of ischemic-HF patients (4, 5), but none addressed the role of BAG3 in ischemic-
HF nor the potential impact of HSPB7 and BAG3 loci on HF severity. We hypothesized that 
these two loci could be involved in susceptibility to syst-HF due to CAD (ischemic-HF) 
and/or in severity of syst- HF due to CAD or DCM. 
 
All participants were of European origin, had a diagnosis of systolic-HF (Left Ventricle 
Ejection Fraction, LVEF, < 45%) and gave written informed consent. The study complies 
with the principles of the Declaration of Helsinki and was approved by local ethics 
committees. In total, 1160 ischemic-HF patients and 1612 controls and 1141 DCM patients 
were studied. Genotyping of rs2234962-BAG3 and rs10927875-HSPB7 was performed with 
TaqMan technology. Disease severity was assessed in patients with Ischemic-HF or DCM as 
4 following: LVEF, Left Ventricle End Diastolic Diameter (LVEDD), NYHA dyspnea at 
inclusion and Age at diagnosis. We analyzed the data following this summarized 
methodology. After quality controls and Hardy-Weinberg equilibrium testing in controls 
(p<0.05), the association between Ischemic- HF and individual genotypes was tested using a 
logistic regression model adjusting on age, gender, and study population in the R statistical 
environment (7). We assumed an additive mode of inheritance and decided to adjust the p-
value threshold following Bonferroni correction for two independent tests (p-value <0.025 
considered significant). Severity assessment in patients was performed via linear regression 
analyses adjusted for age, sex, and origin depending on the SNP genotype exposure. 
 
Considering the allelic odds ratios for rs10927875-HSPB7 and rs2234962-BAG3 associations 
with DCM (0.71 and 0.54 respectively) (3) and the p-value threshold of 0.025, our study had 
a 95% and 99% power to detect similar associations. We observed that rs10927875- HSPB7 
is significantly associated with Ischemic-HF (Table 1), with a MAF lower in patients than in 
controls (0.29 vs. 0.33, p=0.0017, odds ratio 0.96 [0.94-0.98]), which is consistent with a 
protective effect of the T minor variant against Ischemic-HF. No significant association was 
detected between rs2234962-BAG3 and Ischemic-HF (Table 1), even though a trend was 
detected. Regarding severity, rs2234962-BAG3 was significantly associated with LVEDD 
both in DCM (adjusted-p: 0.0056, Table 2, N=1076 patients) and ischemic-HF patients 
(adjustedp:0.01, N=359 patients). In the ischemic-HF population, the major allele T of 
rs2234962-BAG3 was associated with enlarged LVEDD (TT: 64.0 ±8.7 mm; TC: 62.7 ±8.0 
mm and CC:61.8 ±9.8 mm) and thus with a greater severity of the disease. Results are less 
clear in DCM patients although the same trend could be observed between major 
homozygous and heterozygous alleles (TT: 70.9 ±9.6 mm and TC: 69.1 ±9.2 mm 
respectively). No other association could be revealed between the two SNPs and any of the 
other severity criteria. 
 
The protective effect of the T minor allele of rs10927875-HSPB7 against ischemic-HF is 
consistent with previous findings in DCM patients (3). Matkovich and Cappola also 
described SNPs in HSPB7 locus, rs1739840 and rs1739843 respectively, which exhibited a 
lower MAF in Ischemic-HF cases than in controls (0.4126 vs. 0.4735 and 0.367 vs 0.436 
respectively) (5, 6). Finding an association between ischemic-HF and HSPB7 locus but not 
with BAG3 locus suggests that the genetic background of multifactorial systolic-HF is 
different according to its underlying causes. This is meaningful since the pathophysiological 
pathways of these two diseases are different, DCM resulting from a primary myocardial 
defect whereas ischemic-HF is due to ischemia and necrosis. Since HSPB7 locus appears 
involved in both causes, this may reflect a pivotal role of gene(s) in the locus as a poorly 
adaptive process to various triggers. The restricted association of BAG3 locus with DCM 
suggests a more specific role in the context of a primary myocardial defect. rs10927875-
HSPB7 locates in an intron of ZBTB17 on chromosome 1p36, but the locus encompasses 
several other genes—SPEN, HSPB7, CLCNKA and CLCNKB—exhibiting strong linkage 
disequilibrium. HSBP7 is considered as a strong candidate because it exhibits cardiac-
specific expression and some of its variants have been independently associated with 
advanced HF, systolic-HF (8) or with DCM (4-6). A recent study found that HSPB7 is early 
expressed in embryonic heart and have a major role in heart embryogenesis (9).  BAG3 is 
mainly expressed in striated muscle and is involved in anti-apoptosis and anti-proteotoxicity 
pathways (10). rs2234962-BAG3, a non-synonymous SNP (c.T757C, p.C151R) predicted as 
probably damaging by Polyphen, is associated in our study with LVEDD in both ischemic-
HF and CMD populations. The number of T alleles appears related with enlarged LVEDD in 
ischemic-HF patients but this was less clear for DCM patients, possibly due to the very low 
T homozygous DCM patients (9 out of the 1141). A less efficient BAG3 activity may favour 
HF severity but the hypothesis is speculative. Out of the two loci previously associated with 
DCM, we observed that HSPB7 locus was also associated with ischemic-HF whereas BAG3 
locus was not. Conversely, BAG3 locus was associated with LVEDD in both DCM and syst-
HF patients. Our results suggest investigating further the role of these two loci in the 
pathophysiology of HF of various causes. 
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